Navigation Links
Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
Date:7/2/2008

LAVAL, QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has submitted a complete response to the Food and Drug Administration (FDA) per the suggestion of Dr. Douglas Throckmorton, M.D., the FDA's Deputy Director, Center for Drug Evaluation and Research (CDER), as the next step in the regulatory path towards potential U.S. approval of the Company's once-daily formulation of tramadol. The complete response centers on the additional analysis of existing data using the methodology put forward by Dr. John K. Jenkins, M.D., Director for the Office of New Drugs, CDER, in his letter earlier this year.

Upon acceptance for review of the response, the FDA will assign an action date under the Prescription Drug User Fee Act (PDUFA).

About Labopharm's Once-Daily Tramadol Product

Labopharm's once-daily tramadol product is based on the Company's proprietary Contramid(R) technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy. Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 12 countries, including the five largest markets in Europe and Canada and is approved in 19 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
2. Labopharm Reports Results for First Quarter Fiscal 2008
3. Labopharm announces details for first quarter results conference call and annual meeting
4. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
5. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
6. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
7. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
8. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
9. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 18, 2017 , ... The CHP suggests that California drivers can avoid hydroplaning ... down and increasing the space between themselves and other vehicles, according to a January ... Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving ...
(Date:1/19/2017)... Norwalk, CT (PRWEB) , ... January 19, 2017 , ... ... Dr. Sang H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings ... skincare center . , “It is with considerable pleasure to welcome back Dr. Kim ...
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... Seabrook, NH (PRWEB) , ... January 19, 2017 , ... ... develop its business plan and implement new sales and marketing strategies. Grover comes with ... spent the last 5 and a half years as Executive Vice President of Direct ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the American Osteopathic College of Proctology) announced today the opening of 3 ... California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
Breaking Medicine Technology: